Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Enterprise Value (2020 - 2023)

Cullinan Therapeutics has reported Enterprise Value over the past 4 years, most recently at -$466.4 million for Q3 2023.

  • Quarterly results put Enterprise Value at -$466.4 million for Q3 2023, up 19.02% from a year ago — trailing twelve months through Sep 2023 was -$466.4 million (up 19.02% YoY), and the annual figure for FY2022 was -$467.3 million, down 61.1%.
  • Enterprise Value for Q3 2023 was -$466.4 million at Cullinan Therapeutics, up from -$841.8 million in the prior quarter.
  • Over the last five years, Enterprise Value for CGEM hit a ceiling of $1.9 million in Q3 2020 and a floor of -$841.8 million in Q2 2023.
  • Median Enterprise Value over the past 4 years was -$452.3 million (2021), compared with a mean of -$417.8 million.
  • Biggest five-year swings in Enterprise Value: tumbled 36399.03% in 2021 and later grew 29.33% in 2023.
  • Cullinan Therapeutics' Enterprise Value stood at -$208.9 million in 2020, then tumbled by 38.85% to -$290.1 million in 2021, then plummeted by 61.1% to -$467.3 million in 2022, then rose by 0.18% to -$466.4 million in 2023.
  • The last three reported values for Enterprise Value were -$466.4 million (Q3 2023), -$841.8 million (Q2 2023), and -$390.7 million (Q1 2023) per Business Quant data.